Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4748989 | 1.00 | PPM1D (0.38) | PPM1DSMN1; SMN2CHRNB2CHRNA4BTK | |
| SCHEMBL4748991 | 1.00 | PPM1D (0.38) | PPM1DSMN1; SMN2CHRNB2CHRNA4BTK | |
| SCHEMBL19148890 | 0.91 | SMN1; SMN2 (0.36) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22357286 | 0.91 | SMN1; SMN2 (0.36) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL16167661 | 0.91 | SMN1; SMN2 (0.36) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1498724 | 0.85 | CHRNB2 (0.42) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL19149236 | 0.85 | CHRNB2 (0.42) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1498725 | 0.85 | CHRNB2 (0.42) | PPM1DSMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4922240 | 0.84 | BTK (0.44) | PPM1DBTK | |
| SCHEMBL4922245 | 0.84 | BTK (0.44) | PPM1DBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478528-A | Aroyl-substituted tricyclic compound, preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2008119715-A1 | 1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-01-17 | — | — | US | disclosed |
| US-7259177-B2 | Cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-21 | — | — | US | disclosed |
| EP-1599452-B1 | 3-(2-PHENYL-OXAZOL-4-YL METHOXY) CYCLOHEXYLMETHOXY ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS USED AS PPAR MODULATORS FOR TREATING TYPE 2 DIABETES AND ARTERIOSCLEROSIS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015238-A1 | CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | GPR119, PC, ACADM | PPM1D 2542/4885SMN1; SMN2 1559/4885CHRNB2 2205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.